In a recent study, researchers have identified ‘Cytoskeleton-Associated Protein 4 (CKAP4)’ as a potential biomarker for early diagnosis of lung cancer. It has been reported that the level of CKAP4 is high in the blood of patients with stage I lung cancer. It can be used as a potential biomarker for the early diagnosis and treatment of non-small cell and squamous cell lung cancer and may also lead to improved patient outcomes. The study was carried out by a reverse-phase protein array analysis using a monoclonal antibody, known as KU-Lu-1.
This trial was analysed on the blood sample of 271 lung cancer patients and 100 healthy individuals. Generally, lung cancer is diagnosed at an advanced stage due to poor prognosis, therefore its determination at an early stage can be extremely important to improve prognosis. The results of the study provide an evidence that the CKAP4 protein can be a…
